Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the therapy’s maker, Liquidia, has received an additional $50 million under its financing agreement with Healthcare Royalty (HCRx). Per that HCR Agreement, Liquidia has been raising funds by selling HCRx…
Read more
A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH) has completed enrollment. The ADVANCE OUTCOMES trial (NCT03626688) enrolled 728 people with PAH who were on oral background therapies. Participants are being randomly assigned to receive ralinepag at doses…
As an avid reader who lives with a chronic illness, I’ve always looked for stories to which I could relate. When I was a teenager, I read “The Fault in Our Stars” by John Green, which followed the life of a 16-year-old girl with terminal cancer. It was…
Get regular updates to your inbox.
